TAK-385 Phase I Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability Study

NCT02252354 | Completed Phase 1 Results

• 4 other identifiers: TAK-385-10092014-001564-35U1111-1159-566314/WA/1087
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this 2 part study is to look at how TAK-385 is taken up, broken down and removed from the body when given as a radiolabelled oral solution (by mouth) or as an oral tablet (by mouth) followed by a radiolabelled intravenous (IV) infusion (into the arm vein).

Conditions

Healthy Volunteers

Keywords

Drug therapy

Outcome Measures

Primary Outcomes (35)

• Part 1: Time to Reach the Maximum Plasma and Whole Blood Radioactivity Concentration (Cmax) for [14C]-TAK-385

  Tmax: Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax. Radioactivity corresponds to no more than (NMT) 4.7 millibecquerel (MBq) (127 microcurie \[mCi\]). Cmax was calculated as disintegration per minute per mL (DPM/mL). Total \[14C\]-TAK-385 determination of plasma and whole blood samples was determined by accelerator mass spectrometry (AMS) method.

  Day 1 pre-dose and various time-points (up to 288 hours) post-dose

• Part 1: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-385

  Tmax: Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax. Plasma concentrations of TAK-385 were measured by high-performance liquid chromatography with tandem mass spectrometry method (LC-MS/MS). Correction of the LC-MS/MS derived concentrations were based upon the specific activity of the administered radiolabelled drug product (\[14C\]-TAK-385).

  Day 1 pre-dose and various time-points (up to 168 hours) post-dose

• Part 1: Cmax: Maximum Observed Plasma and Whole Blood Radioactivity Concentration for [14C]-TAK-385

  Maximum observed concentration (Cmax) is the peak concentration of a drug after administration, obtained directly from the concentration-time curve. Radioactivity corresponds to NMT 4.7 MBq (127 mCi). Cmax was measured in nanogram equivalent per milliliter (ng eq/mL) and was calculated as disintegration per minute per mL (DPM/mL). Total \[14C\]-TAK-385 determination of plasma and whole blood samples was determined by AMS method.

  Day 1 pre-dose and various time-points (up to 288 hours) post-dose

• Part 1: Cmax: Maximum Observed Plasma Concentration for TAK-385

  Maximum observed concentration (Cmax) is the peak concentration of a drug after administration, obtained directly from the concentration-time curve. Plasma concentrations of TAK-385 were measured by high-performance liquid chromatography with tandem mass spectrometry method (LC-MS/MS). Correction of the LC-MS/MS derived concentrations were based upon the specific activity of the administered radiolabelled drug product (\[14C\]-TAK-385).

  Day 1 pre-dose and various time-points (up to 168 hours) post-dose

• Part 1: AUC(0-inf): Area Under the Plasma and Whole Blood Radioactivity Concentration-time Curve From Time 0 to Infinity for [14C]-TAK-385

  AUC(0-inf) is measure of area under the curve from time 0 to infinity. Radioactivity corresponds to NMT 4.7 MBq (127 mCi). AUC(0-inf) was measured in nanogram equivalent\*hour per milliliter (ng eq\*hr/mL) and was calculated as disintegration per minute per mL (DPM/mL). Total \[14C\]-TAK-385 determination of plasma and whole blood samples was determined by AMS method.

  Day 1 pre-dose and various time-points (up to 288 hours) post-dose

• Part 1: AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-385

  AUC(0-inf) is area under the concentration-time curve from time 0 to infinity. Plasma concentrations of TAK-385 were measured by high-performance liquid chromatography with tandem mass spectrometry method (LC-MS/MS). Correction of the LC-MS/MS derived concentrations were based upon the specific activity of the administered radiolabelled drug product (\[14C\]-TAK-385) .

  Day 1 pre-dose and various time-points (up to 168 hours) post-dose

• Part 1: AUC(0-168): Area Under the Plasma and Whole Blood Radioactivity Concentration-Time Curve From Time 0 to 168 Hours Postdose for [14C]-TAK-385

  AUC(0-168) is measure of area under the curve over the dosing interval (tau),where tau is the length of the dosing interval: 168 hours in this study (AUC(0-168\]). Radioactivity corresponds to NMT 4.7 MBq (127 mCi). It was calculated as disintegration per minute per mL (DPM/mL). Total \[14C\]-TAK-385 determination of plasma and whole blood samples was determined by AMS method.

  Day 1 pre-dose and various time-points (up to 288 hours) post-dose

• Part 1: AUC(0-168): Area Under the Plasma Concentration-Time Curve From Time 0 to 168 Hours Postdose for TAK-385

  AUC(0-168) is measure of area under the curve over the dosing interval (tau) (AUC(0-tau\]), where tau is the length of the dosing interval -168 hours in this study). Plasma concentrations of TAK-385 were measured by high-performance liquid chromatography with tandem mass spectrometry method (LC-MS/MS). Correction of the LC-MS/MS derived concentrations were based upon the specific activity of the administered radiolabelled drug product (\[14C\]-TAK-385).

  Day 1 pre-dose and various time-points (up to 168 hours) post-dose

• Part 1: Terminal Phase Elimination Half-Life (t1/2z) in Plasma and Whole Blood Radioactivity for [14C]-TAK-385

  Terminal phase elimination half-life (t1/2z) is the time required for half of the drug to be eliminated from the blood. Radioactivity corresponds to NMT 4.7 MBq (127 mCi). It was calculated as disintegration per minute per mL (DPM/mL). Total \[14C\]-TAK-385 determination of plasma and whole blood samples was determined by AMS method.

  Day 1 pre-dose and various time-points (up to 288 hours) post-dose

• Part 1: Terminal Phase Elimination Half-Life (t1/2z) in Plasma for TAK-385

  Terminal phase elimination half-life (t1/2z) is the time required for half of the drug to be eliminated from the blood. Plasma concentrations of TAK-385 were measured by high-performance liquid chromatography with tandem mass spectrometry method (LC-MS/MS). Correction of the LC-MS/MS derived concentrations were based upon the specific activity of the administered radiolabelled drug product (\[14C\]-TAK-385).

  Day 1 pre-dose and various time-points (up to 168 hours) post-dose

• Part 1: Overall Cumulative Percent Recovery of Total Dosed Radioactivity in Urine and Feces

  Overall cumulative percent of radioactive dose recovered in urine and feces is the total radioactivity excreted in urine and feces divided by the amount of total radioactivity dosed for each participant. Total \[14-C\] determination of urine and feces samples were determined by Liquid Scintillation Counting (LSC).

  Day 1 pre-dose and various time-points (up to Day 288) post-dose

• Part 2: Tmax : Time to Reach the Maximum Plasma Radioactivity Concentration (Cmax) for [14C]-TAK-385

  Tmax: Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax. Radioactivity corresponds to NMT 37.0 kilobecquerel (kBq) (1000 nanocurie \[nCi\]). Total radioactivity and \[14C\]-TAK-385 determination of plasma samples was determined by AMS.

  Day 1 pre-dose and various time-points (up to 168 hours) post-dose

• Part 2: Tmax : Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-385

  Tmax: Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax.

  Day 1 pre-dose and various time-points (up to 168 hours) post-dose

• Part 2: Cmax: Maximum Observed Plasma Radioactivity Concentration for [14C]-TAK-385

  Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve. Radioactivity corresponds to NMT 37.0 kBq (1000 nCi).Total radioactivity and \[14C\]-TAK-385 determination of plasma samples was determined by AMS.

  Day 1 pre-dose and various time-points (up to 168hours) post-dose

• Part 2: Cmax: Maximum Observed Plasma Radioactivity Concentration for TAK-385

  Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.

  Day 1 pre-dose and various time-points (up to 168 hours) post-dose

• Part 2: AUC(0-inf): Area Under the Plasma Radioactivity Concentration-time Curve From Time 0 to Infinity for [14C]-TAK-385

  AUC(0-inf) is measure of area under the curve from time 0 to Infinity. Radioactivity corresponds to NMT 37.0 kBq (1000 nCi).AUC(0-inf) was corrected according to Hamilton Pool result.Total radioactivity and \[14C\]-TAK-385 determination of plasma samples was determined by AMS.

  Day 1 pre-dose and various sampling time-points (up to 168 hours) post-dose

• Part 2: AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-385

  AUC(0-inf) is measure of area under the curve from time 0 to Infinity.

  Day 1 pre-dose and various time-points (up to 288 hours) post-dose

• Part 2: AUC(0-168): Area Under the Plasma Radioactivity Concentration-Time Curve From Time 0 to 168 Hours Postdose for [14C]-TAK-385

  AUC(0-168) is measure of area under the curve over the dosing interval (tau), where tau is the length of the dosing interval :168 hours in this study (AUC(0-tau\]). AUC(0-168) was corrected according to Hamilton Pool result.Radioactivity corresponds to NMT 37.0 kBq (1000 nCi).Total radioactivity and \[14C\]-TAK-385 determination of plasma samples was determined by AMS.

  Day 1 pre-dose and various time-points (up to 168 hours) post-dose

• Part 2: AUC(0-168): Area Under the Plasma Concentration-Time Curve From Time 0 to 168 Hours Postdose for TAK-385

  AUC(0-168) is measure of area under the curve over the dosing interval (tau),where tau is the length of the dosing interval: 168 hours in this study (AUC(0-tau\]). AUC was corrected using the Hamilton Pool Data to get an AUC for TAK-385.

  Day 1 pre-dose and various time-points (up to 168 hours) post-dose

• Part 2: Terminal Phase Elimination Half-Life (t1/2z) in Plasma Radioactivity for [14C]-TAK-385

  Terminal phase elimination half-life (t1/2z) is the time required for half of the drug to be eliminated from the blood. Radioactivity corresponds to NMT 37.0 kBq (1000 nCi).Total radioactivity and \[14C\]-TAK-385 determination of plasma samples was determined by AMS.

  Day 1 pre-dose and various time-points (up to 168 hours) post-dose

• Part 2: Terminal Phase Elimination Half-Life (t1/2z) in Plasma for TAK-385

  Terminal phase elimination half-life (t1/2z) is the time required for half of the drug to be eliminated from the blood.

  Day 1 pre-dose and various time-points (up to 168 hours) post-dose

• Part 2: Absolute Bioavailability for the Oral Tablet Formulation

  Absolute bioavailability, defined as the fraction or percentage of the unchanged, orally administered dose that is systemically available, relative to the total dose administered intravenously. AUC was corrected using the Hamilton Pool Data to get an AUC for TAK-385

  Day 1 pre-dose and various time-points (up to 168 hours) post-dose

• Part 1: Excretion of TAK-385 and Its Metabolites in Human Feces as Percent Radioactivity

  Amount of total \[14\]C, TAK-385, metabolite A, B, and C, and others excreted from feces, calculated as percentage of recovered radioactivity, are reported. Others were calculated by subtraction of the sum of the values for TAK-385, Metabolite-A, Metabolite-B, and Metabolite-C from the value of the total radioactivity (total \[14\]C).Radioactivity corresponds to NMT 4.7 MBq (127 mCi).

  0 to 191 hours post-dose

• Part 1: Excretion of TAK-385 and Its Metabolites in Human Urine as Percent Radioactivity

  Amount of total \[14\]C, TAK-385, metabolite A, B, and C, and others excreted from urine, calculated as percentage of recovered radioactivity, are reported. Others were calculated by subtraction of the sum of the values for TAK-385, Metabolite-A, Metabolite-B, and Metabolite-C from the value of the total radioactivity (total \[14\]C).Radioactivity corresponds to NMT 4.7 MBq (127 mCi).

  0 to 144 hours post-dose

• Part 1: Excretion of TAK-385 and Its Metabolites in Human Feces as Percentage of Dose

  Amount of total \[14\]C, TAK-385, metabolite A, B, and C, and others excreted from feces, calculated as percentage of dose. Others were calculated by subtraction of the sum of the values for TAK-385, Metabolite-A, Metabolite-B, and Metabolite-C from the value of the total \[14\]C.

  0 to 191 hours post-dose

• Part 1: Excretion of TAK-385 and Its Metabolites in Human Urine as Percentage of Dose

  Amount of total \[14\]C, TAK-385, metabolite A, B, and C, and others excreted from urine, calculated as percentage of dose. Others were calculated by subtraction of the sum of the values for TAK-385, Metabolite-A, Metabolite-B, and Metabolite-C from the value of the total \[14\]C.

  0 to 144 hours post-dose

• Part 1: [14]C Distribution Profile From TAK-385 and Metabolites A, B, and C in Plasma Pools at Hour 1 Post-dose

  Percentage of \[14\]C as measured from TAK-385, metabolite A and B, and metabolite C in the plasma pools were calculated as the percentage of dose administered.

  Hour 1 post-dose

• Part 1: [14]C Distribution Profile From TAK-385 and Metabolites A, B, and C in Plasma Pools at Hour 2 Post-dose

  Percentage of \[14\]C as measured from TAK-385, metabolite A and B, and metabolite C in the plasma pools were calculated as the percentage of dose administered.

  Hour 2 post-dose

• Part 1: [14]C Distribution Profile From TAK-385 and Metabolites A, B, and C in Plasma Pools at Hour 4 Post-dose

  Percentage of \[14\]C as measured from TAK-385, metabolite A and B, and metabolite C in the plasma pools were calculated as the percentage of dose administered.

  Hour 4 post-dose

• Part 1: [14]C Distribution Profile From TAK-385 and Metabolites A, B, and C in Plasma Pools at Hour 8 Post-dose

  Percentage of \[14\]C as measured from TAK-385, metabolite A and B, and metabolite C in the plasma pools were calculated as the percentage of dose administered.

  Hour 8 post-dose

• Part 1: [14]C Distribution Profile From TAK-385 and Metabolites A, B, and C in Plasma Pools at Hour 12 Post-dose

  Percentage of \[14\]C as measured from TAK-385, metabolite A and B, and metabolite C in the plasma pools were calculated as the percentage of dose administered.

  Hour 12 post-dose

• Part 1: [14]C Distribution Profile From TAK-385 and Metabolites A, B, and C in Plasma Pools at Hour 24 Post-dose

  Percentage of \[14\]C as measured from TAK-385, metabolite A and B, and metabolite C in the plasma pools were calculated as the percentage of dose administered.

  Hour 24 post-dose

• Part 1: [14]C Distribution Profile From TAK-385 and Metabolites A, B, and C in Plasma Pools at Hour 36 Post-dose

  Percentage of \[14\]C as measured from TAK-385, metabolite A and B, and metabolite C in the plasma pools were calculated as the percentage of dose administered.

  Hour 36 post-dose

• Part 1: [14]C Distribution Profile From TAK-385 and Metabolites A, B, and C in Plasma Pools at Hour 48 Post-dose

  Percentage of \[14\]C as measured from TAK-385, metabolite A and B, and metabolite C in the plasma pools were calculated as the percentage of dose administered.

  Hour 48 post-dose

• Part 1: [14]C Distribution Profile From TAK-385 and Metabolites A, B, and C in Plasma Pools at Hour 72 Post-dose

  Percentage of \[14\]C as measured from TAK-385, metabolite A and B, and metabolite C in the plasma pools were calculated as the percentage of dose administered.

  Hour 72 post-dose

Secondary Outcomes (6)

• Part 1: Apparent Oral Clearance (CL/F) for TAK-385

  Day 1 pre-dose and various time-points (up to 168 hours) post-dose

• Part 2: Apparent Oral Clearance (CL/F) for TAK-385

  Day 1 pre-dose and various time-points (up to 168 hours) post-dose

• Part 1: Volume of Distribution (Vz/F) for TAK-385

  Day 1 pre-dose and various time-points (up to 168 hours) post-dose

• Part 2: Volume of Distribution (Vz/F) for TAK-385

  Day 1 pre-dose and various time-points (up to 168 hours) post-dose

• Part 2: Overall Cumulative Percent Recovery of Total Dosed Radioactivity in Urine and Feces

  Day 1 pre-dose and various time-points (up to 72 hours) post-dose for urine; Day 1 pre-dose and various time-points (up to 48 hours) post-dose

Study Arms (2)

Part 1: [14C]-TAK-385

EXPERIMENTAL

\[14C\]-TAK-385 80 mg, solution, orally, once on Day 1.

Drug: [14C]-TAK-385 Oral Solution

Part 2: TAK-385 + [14C]-TAK-385 IV

EXPERIMENTAL

TAK-385 80 mg, tablets, orally, and \[14C\]-TAK-385 80 μg, infusion, intravenous once on Day 1.

Drug: TAK-385 Tablets; Drug: [14C]-TAK-385 Solution for Intravenous Infusion

Interventions

[14C]-TAK-385 Oral Solution DRUG

TAK-385 oral radiolabelled solution

Part 1: [14C]-TAK-385

TAK-385 Tablets DRUG

TAK-385 tablets 2 X 40 mg

Part 2: TAK-385 + [14C]-TAK-385 IV

[14C]-TAK-385 Solution for Intravenous Infusion DRUG

TAK-385 intravenous (IV) radiolabelled solution

Part 2: TAK-385 + [14C]-TAK-385 IV

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Signs a written, informed consent form prior to the initiation of any study procedures.
• Is a healthy male, aged 18 to 55; inclusive on Day-1.
• Is capable of understanding and complying with protocol requirements.
• Weighs at least 50 kg and has a body mass index (BMI) between 18.0 and 35.0 kg/m\^2, inclusive at Screening or Day-1.
• In the opinion of the investigator, is in good healthy condition on the basis of a pre-study physical examination, medical history, vital signs, electrocardiogram, and the results of blood biochemistry, hematology, and serology test and urinalysis at Screening and Day -1.
• A male participant who is nonsterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from signing of informed consent throughout the duration of the study and for 90 days after last dose.

You may not qualify if:

• Has received any investigational compound within 45 days prior to Day -1.
• Has received TAK-385 in a previous clinical study.
• Has a resting systolic blood pressure ≤90 mmHg or ≥140 mmHg and a resting diastolic blood pressure ≤50 mmHg or ≥90 mmHg in supine position at Screening or Day-1.
• QTc (Fridericia's correction) is \>450 msec at Screening or at Day -1 as read on the printout of the ECG produced by the electrocardiogram (ECG) equipment and evaluated by the investigator
• Has active liver disease or jaundice, or with alanine aminotransferase (ALT),aspartate aminotransferase (AST), or bilirubin (total bilirubin) \>1.5 times the upper limit of normal (ULN) in the clinical laboratory tests at VISIT 1 and 2. The participant has positive test results for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (anti-HCV) or known history of human immunodeficiency virus (HIV) at Screening.
• Has a resting pulse and heart rate (as read on ECG) \<45 beats per minute (bpm) or \>100 bpm at Screening or Day -1.
• Has had an acute, clinically significant illness within 30 days prior to Day -1.
• Has a history or clinical manifestations of significant metabolic (including diabetes mellitus, hypercholesterolemia, or dyslipidemia), hematologic, pulmonary, cardiovascular,gastrointestinal, neurological, rheumatologic, skin and subcutaneous tissue disorders,infectious, hepatic, renal, urologic, immunologic, psychiatric or mood disorders (including any past history of suicide attempt), or history of lactose intolerance.
• Has a family history of bleeding disorders.
• Has current or recent (within 6 months) history of gastrointestinal disease that would be expected to influence the absorption of drugs (ie, history of malabsorption,esophageal reflux, peptic ulcer disease, erosive esophagitis, frequent heartburn, or any surgical intervention).
• Has irregular defecation patterns (less than one defecation per two days or excessive diarrhea) and/or has a history of changes in bowel habits with daily routine or environment changes.
• Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 millisievert (mSv) in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study
• Has a history of abdominal surgery (except laparoscopic cholecystectomy or uncomplicated appendectomy), thoracic or nonperipheral vascular surgery within 6 months prior to Day - 1.
• Has a history of cancer, other than basal cell or Stage 1 squamous cell carcinoma of the skin that has not been in remission for at least 5 years prior to Day 1.
• Has significant cardiovascular disease including, but not limited to, a history of myocardial infarction, coronary angioplasty or bypass graft, unstable angina pectoris, transient ischemic attacks, clinically significant abnormal ECGs, New York Heart Association (NYHA) Functional Classification III or IV, or documented cerebrovascular accident within 6 months prior to Day -1.

Sponsors & Collaborators

• Takeda: lead

Study Sites (1)

Unknown Facility

Nottingham, United Kingdom

Location

MeSH Terms

Interventions

relugolix; Infusions, Intravenous

Intervention Hierarchy (Ancestors)

Administration, Intravenous; Drug Administration Routes; Drug Therapy; Therapeutics; Infusions, Parenteral

Results Point of Contact

• Title: Medical Director
• Organization: Takeda

clinicaltrialregistry@tpna.com

+1-877-825-3327

Study Officials

• Medical Director Clinical Science

  Takeda

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 26, 2014
• First Posted: September 30, 2014
• Study Start: September 1, 2014
• Primary Completion: October 1, 2014
• Study Completion: October 1, 2014
• Last Updated: October 27, 2016
• Results First Posted: December 1, 2015

Record last verified: 2016-09

Locations

GB (1)